

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

JC20 Rec'd PCT/A 07 JUL 2005

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete #Knot'n</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	July 7, 2005
		First Named Inventor	Valerie AUTIER et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	MERCK-3029
Sheet	2	of	2

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
all	6	NAOKI ET AL.: "A novel enhancer of insulinotropic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta cells via a new cellular mechanism" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 297, no. 3, 2001, pages 953-960 XP002263095.	
one	7	OHTA et al.: "JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 367, 1999, pages 91-99, XP002263096.	
one	8	ESTOPINAN GARCIA V et al: "Perspectives of the immunosuppressive treatment for the prevention of diabetes mellitus type I" ANALES DE MEDICINA INTERNA 1992 SPAIN, vol. 9, no. 10, 1992, pages 471-472, XP009031857	
am	9	MANDRUP-POULSEN T R ET AL: Cyclosporin immunosuppression induces clinical remission and improved 'beta1-cell function in newly diagnosed insulin-dependent diabetics: A national and international multicentre study" UGESKRIFT FOR LAEGER 1990 DENMARK, vol. 152, no. 27, 1990, pages 1963-1969, XP009031858	
am	10	CONNICK ET AL.: "The role of kynurenines in diabetes mellitus" MEDICAL HYPOTHESES, vol.; 18, no. 4, 1985, pages 371-376, XP009021813	

Examiner Signature	<i>Rebecca Hughes</i>	Date Considered	08/03/2007
-----------------------	-----------------------	--------------------	------------

\* EXAMINER: Initial # reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.